Boston, MA, June 23, 2025 – Abrax Japan, Inc., a biotechnology company pioneering a novel class of topical therapies for metabolic and dermatological disorders, today announced its successful participation in the BIO International Convention 2025, held last week in Boston.
During the event, the Abrax team held productive one-on-one meetings with major pharmaceutical companies—including Eli Lilly—as well as leading venture capital firms and global contract research organizations (CROs). Across the board, attendees expressed strong interest in Abrax’s platform, highlighting its novelty and clinical potential.
Abrax’s lead asset, a topically applied compound targeting fat metabolism and skin health, is designed to treat a range of conditions from obesity to inflammatory skin diseases—without systemic side effects.
“We were thrilled by the reception we received at BIO,” said Jo Narita, CEO of Abrax Japan. “It was clear that our non-invasive, skin-delivered platform resonated with pharma and investors alike, especially as the industry looks for differentiated approaches to metabolic and inflammatory disorders.”
Dr. Taku Kambayashi, Co-founder and Chief Scientific Officer, added: “Our preclinical data continues to support the systemic metabolic benefits of our topical formulation. We’re excited to be building momentum with top-tier partners who recognize the value and versatility of this technology.”
As part of its next phase of development, Abrax is actively seeking investment to support its first-in-human clinical trials, which are scheduled to begin in early 2026. The company’s lead program is on track for IND-enabling studies and is advancing toward regulatory submission.
If you have any questions or comments or would like to request an interview, please contact Abrax Japan, and our representative will get in touch with you promptly.
